JP2008522162A - Ｍｅｒの診断用および治療用の作用薬 - Google Patents

Ｍｅｒの診断用および治療用の作用薬 Download PDF

Info

Publication number
JP2008522162A
JP2008522162A JP2007543518A JP2007543518A JP2008522162A JP 2008522162 A JP2008522162 A JP 2008522162A JP 2007543518 A JP2007543518 A JP 2007543518A JP 2007543518 A JP2007543518 A JP 2007543518A JP 2008522162 A JP2008522162 A JP 2008522162A
Authority
JP
Japan
Prior art keywords
mer
glycoform
molecular weight
tyrosine kinase
receptor tyrosine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007543518A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008522162A5 (OSRAM
Inventor
グラハム，ダグラス，キム
セイザー，スーザン，ルイス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Colorado Boulder
Original Assignee
University of Colorado Boulder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Colorado Boulder filed Critical University of Colorado Boulder
Publication of JP2008522162A publication Critical patent/JP2008522162A/ja
Publication of JP2008522162A5 publication Critical patent/JP2008522162A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Communicable Diseases (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
JP2007543518A 2004-11-24 2005-11-23 Ｍｅｒの診断用および治療用の作用薬 Pending JP2008522162A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63019204P 2004-11-24 2004-11-24
PCT/US2005/042724 WO2006058202A2 (en) 2004-11-24 2005-11-23 Mer diagnostic and therapeutic agents

Publications (2)

Publication Number Publication Date
JP2008522162A true JP2008522162A (ja) 2008-06-26
JP2008522162A5 JP2008522162A5 (OSRAM) 2009-01-15

Family

ID=36498546

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2007543518A Pending JP2008522162A (ja) 2004-11-24 2005-11-23 Ｍｅｒの診断用および治療用の作用薬

Country Status (5)

Country Link
US (2) US20080267975A1 (OSRAM)
EP (1) EP1825005B1 (OSRAM)
JP (1) JP2008522162A (OSRAM)
CA (1) CA2630475A1 (OSRAM)
WO (1) WO2006058202A2 (OSRAM)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2018504105A (ja) * 2014-12-22 2018-02-15 ザ ロックフェラー ユニバーシティー 抗ｍｅｒｔｋアゴニスト抗体及びその使用
KR101877984B1 (ko) * 2013-10-07 2018-07-12 이화여자대학교 산학협력단 항염증 물질을 스크리닝하는 방법

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2555763A1 (en) * 2004-01-29 2005-08-11 Asahi Kasei Pharma Corporation Therapeutic agent for vasospasm accompanying bypass operation
WO2008098139A2 (en) 2007-02-07 2008-08-14 The Regents Of The University Of Colorado Axl tyrosine kinase inhibitors and methods of making and using the same
PT3241840T (pt) * 2010-01-22 2022-10-13 Univ Leland Stanford Junior Inibição da sinalização de axl em terapêutica anti-metastática
WO2012149018A1 (en) * 2011-04-25 2012-11-01 The Regents Of The University Of Colorado Mer tyrosine kinase inhibitors and methods of making and using the same
US9879061B2 (en) 2011-12-15 2018-01-30 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of AXL/GAS6 signaling in the treatment of liver fibrosis
PT3326622T (pt) 2012-12-14 2021-04-07 Univ Leland Stanford Junior Péptidos axl modificados e sua utilização na inibição da sinalização de axl em terapêutica anti-metastática
US10137173B2 (en) 2014-10-20 2018-11-27 Aravive Biologics, Inc. Antiviral activity of Gas6 inhibitor
CA3068672A1 (en) 2017-06-28 2019-01-03 The Rockefeller University Anti-mertk agonistic antibody-drug conjugates and uses thereof
AU2020401319A1 (en) 2019-12-13 2022-06-30 Alector Llc Anti-MerTK antibodies and methods of use thereof
CN111812014B (zh) * 2020-08-05 2023-04-18 上海市血液中心 一种基于纳米材料的血小板抗体检测方法和血小板保存方法
CA3217372A1 (en) * 2021-05-14 2022-11-17 Masoud TAVAZOIE Mertk peptides and uses thereof
JP2024527262A (ja) 2021-06-16 2024-07-24 アレクトル エルエルシー 二重特異性抗ＭｅｒＴＫ及び抗ＰＤＬ１抗体ならびにその使用方法
JP2024527493A (ja) 2021-06-16 2024-07-25 アレクトル エルエルシー 一価の抗ＭｅｒＴＫ抗体及びその使用方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US6018026A (en) * 1988-01-22 2000-01-25 Zymogenetics, Inc. Biologically active dimerized and multimerized polypeptide fusions
US5554601A (en) * 1993-11-05 1996-09-10 University Of Florida Methods for neuroprotection
US5585269A (en) * 1994-06-02 1996-12-17 The University Of North Carolina At Chapel Hill Isolated DNA encoding c-mer protooncogene
US7339033B2 (en) * 1998-06-26 2008-03-04 Genentech, Inc. Pro1481
EP1272217A1 (en) * 2000-04-13 2003-01-08 Vlaams Interuniversitair Instituut voor Biotechnologie (VIB) Use of inhibition of a gas6 function or of a gas6 receptor for preventing and treating a cardiovascular disease
US20040018513A1 (en) * 2002-03-22 2004-01-29 Downing James R Classification and prognosis prediction of acute lymphoblastic leukemia by gene expression profiling
US20040157774A1 (en) * 2002-09-24 2004-08-12 Jing Yang Epitope-tagged recombinant Growth Arrest Specific Gene 6 protein

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101877984B1 (ko) * 2013-10-07 2018-07-12 이화여자대학교 산학협력단 항염증 물질을 스크리닝하는 방법
JP2018504105A (ja) * 2014-12-22 2018-02-15 ザ ロックフェラー ユニバーシティー 抗ｍｅｒｔｋアゴニスト抗体及びその使用

Also Published As

Publication number Publication date
WO2006058202A2 (en) 2006-06-01
CA2630475A1 (en) 2006-06-01
WO2006058202A3 (en) 2007-06-07
US20120135424A1 (en) 2012-05-31
EP1825005A2 (en) 2007-08-29
EP1825005A4 (en) 2009-04-01
EP1825005B1 (en) 2015-07-15
US20080267975A1 (en) 2008-10-30

Similar Documents

Publication Publication Date Title
US20120135424A1 (en) Mer diagnostic and therapeutic agents
EP3802922B1 (en) Novel immune checkpoint inhibitors
WO2010054195A2 (en) Markers and methods for assessing and treating lupus patients susceptible to photoprovocation
US20200255825A1 (en) Biological materials and therapeutic uses thereof
US8962808B2 (en) EGFR-related polypeptides and methods of use
US20090214517A1 (en) Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease
JP2010512781A (ja) Ｖｅｇｆｒの変化体ならびに妊娠関連の医学的状態の診断および処置におけるその使用
US9745347B2 (en) PAR1 and PAR2 c-tail peptides and peptide mimetics
WO2001019986A1 (fr) Recepteur d'un leucotriene peptidique
US8546324B2 (en) Short-form human MD-2 as a negative regulator of toll-like receptor 4 signaling
WO2005011619A2 (en) Lung-expressed polypeptides
JPH10502252A (ja) Ｄｐ−１及びその他のｄｐタンパク質の阻害剤のアッセイ
WO2006014903A2 (en) Compositions and methods of use for adam12 antagonists in treating disease
US7105315B2 (en) Transmembrane protein differentially expressed in cancer
US7141365B2 (en) Methods for diagnosing a mucin production associated disease condition
AU2004234532A1 (en) SPEX compositions and methods of use
JP4346540B2 (ja) 絨毛外栄養膜細胞特異的蛋白質
JP2002541843A (ja) プロテアーゼ活性化受容体２の変異体
US20100028867A1 (en) LRRTM1 Compositions and Methods of Their Use for the Diagnosis and Treatment of Cancer
US20040115682A1 (en) Novel scavenger receptor class a protein
AU2006200373B2 (en) Novel tumor supressor encoding nucleic acid, PTX1, and methods of use thereof
WO2002095025A1 (fr) Nouveau smg-1
JP2004518409A (ja) 新規な腫瘍抑制因子をコードする核酸、ｐｔｘ１、およびその使用方法
WO2004033643A2 (en) Methods of use of a dna helicase in the diagnosis and treatment of colon and lung cancer
WO2003018776A9 (en) IDENTIFICATION OF THE IκBNS PROTEIN AND ITS PRODUCTS

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20070724

RD01 Notification of change of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7426

Effective date: 20070724

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20081118

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20081118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20111115

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120215

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20120215

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20120301

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20120515